Evolus (EOLS) Moves 5.5% Higher: Will This Strength Last?

Group 1 - Evolus, Inc. shares increased by 5.5% to close at $15.04, with notable trading volume and a 41.6% gain over the past four weeks [1][2] - The company received FDA approval for Evolysse Form and Evolysse Smooth injectable hyaluronic acid gels, marking its entry into the U.S. HA dermal filler market and expanding its total addressable market by 78% to approximately $6 billion [2] - Quarterly earnings are expected to be $0.06 per share, reflecting a year-over-year increase of 142.9%, with revenues projected at $79 million, up 29.5% from the previous year [3] Group 2 - The consensus EPS estimate for Evolus has been revised 100% lower over the last 30 days, indicating a negative trend in earnings estimate revisions, which typically does not lead to price appreciation [4] - Evolus holds a Zacks Rank of 3 (Hold), indicating a neutral outlook [4] - The company is part of the Zacks Medical - Products industry, which includes Verano Holdings Corp., also holding a Zacks Rank of 3 [4][5]